We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Off-Label Promotion Under Scrutiny by DOJ

05 June 2008

Genetic Engineering & Biotechnology News
In a continuing shift of enforcement strategy, the U.S. Department of Justice has firmly taken control of off-label use allegations against pharmaceutical, biotechnology, and medical device manufacturers. Various U.S. attorneys’ offices around the country and especially in Washington, D.C., now enforce existing legalities in the life science industry through the Food, Drug and Cosmetic Act, the Anti-Kickback Statute, and the False Claims Act.


Loading data